الفهرس 
Historical reviewOnly 14 pages are availabe for public view
 |  | from | 183 |  |  |
| | | from | 183 | | |
Abstract
Summary and conclusions [115] Summary and conclusions Scabies is a very common dermatological condition and a major public health burden globally that affects people of all races and social classes and is considered as one of the 50th most common infectious diseases worldwide (Feldmeier et al., 2009, Hay et al., 2010 and Murray et al., 2012). There are numerous topical acaricides like permethrin, benzyl benzoate, crotamiton, or malathion (Chosidow 2006). However, they should be applied to the whole skin surface. This method is messy, smelly, difficult in young children and multiple doses of these drugs are generally required which is not ideal for mass treatment in outbreaks (McCarthy et al., 2004 and Strong et al., 2007). Regarding ivermectin (IVM), which is the only available oral drug, it has no ovicidal activity, needs to be repeated which may lead to neurotoxicity, not safe in young children, during pregnancy or breast feeding and resistance to it has been recorded (Currie et al,. 2004, Ndyomugyenyi et al., 2008, Mounsey et al. 2009, Currie. et al., 2010, Westerloo, 2014 and Bernigaud et al., 2016). In view of these facts significant effort is devoted to develop new, safe, and effective drug for scabies. Moxidectin is currently under consideration as a promising alternative drug (Mounsey et al., 2016). The present study aimed to evaluate the efficacy of moxidectin as a new acaricidal drug against Sarcoptes scabiei both in vitro and in vivo in experimentally infected-rabbits compared with ivermectin from the parasitological point of view.